Bizarre Patents
Pet Toilet-Like Water Disk and Food Storage
One pet-friendly inventor patented "a device for watering pets, e.g., a dog or cat." The device, he helpfully noted, "has the general shape of a toilet."
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8097707 | Compositions and processes for preparing 13-deoxy-anthracyclines 13-benzenesulfonylhydrazone anthracyclines useful in producing improved yields in the synthesis 13-deoxyanthracyclines, and an improved method of reducing 13-benzene-sulfonylhydrazone anthracyclines to 13-deoxyanthracyclines wherein the reduction reaction is maintai... | 01/17/2012 |
| 7772379 | Compositions and processes for preparing 13-deoxy-anthracyclines 13-benzenesulfonylhydrazone anthracyclines useful in producing improved yields in the synthesis 13-deoxyanthrcyclines, and an improved method of reducing 13-benzene-sulfonylhydrazone anthracyclines to 13-deoxyanthrcyclines wherein the reduction reaction is maintaine... | 08/10/2010 |
| 7485707 | Thermally stable crystalline epirubicin hydrochloride and method of making the same A crystalline form of epirubicin hydrochloride, named herein as “type II” crystalline epirubicin hydrochloride, has excellent thermal stability. Type II crystalline epirubicin hydrochloride has a powder X-ray diffraction pattern having average values of diffract... | 02/03/2009 |
| 7402556 | Prodrugs activated by plasmin and their use in cancer chemotherapy The product of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide having a plasmin peptide substrate of 2-4 amino acids and mono- or di-peptide linkage, a stabilizing group and, optionally, a linker group. The ... | 07/22/2008 |
| 7388083 | Epimerization of 4′-C bond and modification of 14-CH-(CO)-fragment in anthracyclin antibiotics A method of synthesizing R1, R2-substituted-4′ (ax. or eq.)-OH anthracyclines and their corresponding salts of Formula (1) from daunorubicin or N-Trifluoroacetyl-4-R1-derivatives of daunorubicin, wherein R1 is defined as H, OH, and 4′-HO is defined as ax[ial]. T... | 06/17/2008 |
| 7345023 | Treatment of hyperproliferative conditions of body surfaces The present invention relates to pharmaceutical formulations comprising an anthracycline and the uses thereof for treatment of clinical conditions of body surfaces such as skin and mucosal membranes, wherein abnormal cell differentiation and/or hyperproliferation is... | 03/18/2008 |
| 7300787 | strains and use thereof in fermentation for L-lactic acid production The present invention relates to L-lactic acid producing bacterial strains, including Lactobacilli such as NRRL B-30568 (ADM B64), NRRL B-30569 (ADM DEC2-2B), NRRL B-30570 (ADM RP1A-4E), NRRL B-30571 (ADM RP2-1C), NRRL B-30572 (ADM RP3-1E), NRRL, B-30573 (ADM... | 11/27/2007 |
| 7270808 | Cyclodextrin-based polymers for therapeutics delivery The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug... | 09/18/2007 |
| 7244829 | Compositions and processes for preparing 13-deoxy-anthracyclines 13-benzenesulfonylhydrazone anthracyclines useful in producing improved yields in the synthesis 13-deoxyanthrcyclines, and an improved method of reducing 13-benzene-sulfonylhydrazone anthracyclines to 13-deoxyanthrcyclines wherein the reduction reaction is maintaine... | 07/17/2007 |
| 7163918 | Iodothyronine compositions The present invention relates to compositions comprising thyroxine (T4) and triiodothyronine (T3). More specifically, the invention relates to thyroxine (T4) and triiodothyronine (T3) compositions that include a peptide carrier and thyroxine (T4) and triiodothyronin... | 01/16/2007 |
| 7153946 | Molecular conjugates for use in treatment of cancer A molecular conjugate is provided having the formula: wherein R1 is a de-hydroxyl or de-amino moiety respectively of a hydroxyl-bearing or amino-bearing biologically active molecule or an analog or der... | 12/26/2006 |
| 7122553 | Liposomal formulation of irinotecan The present invention is for novel compositions and methods for treating cancer, particularly, for treating cancer in mammals and more particularly in humans. The therapeutic compositions of the present invention include liposome entrapped irinotecan in which the li... | 10/17/2006 |
| 7115573 | Prodrug compounds with an isoleucine The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide having an isoleucine residue, a stabilizing group and, optionally, a linker group. The prodrug is clea... | 10/03/2006 |
| 7115576 | Water-soluble antibiotic comprising an amino sugar, in the form of a polysaccharide conjugate The invention relates to novel pharmaceutical forms for antibiotics containing amino sugar, amphotericin B, daunorubicin and doxorubicin, in which the known side effects are reduced and which can be used in a simple manner. The antimycotic agent B is nephrotoxic. Th... | 10/03/2006 |
| 7109177 | Methods and compositions for the manufacture of C-3′ and C-4′ anthracycline antibiotics The present invention discloses new and novel substituted anthracyclines with modified alkyl-aromatic ring substitutions on the C-3′ of the sugar moiety or modified or unmodified alkyl-aromatic ring substitutions at the C-4′ of the sugar moiety. It also disclose... | 09/19/2006 |
| 7091188 | Stabilization of amrubicin hydrochloride A stabilized amrubicin hydrochloride composition which comprises 3 to 8 wt. % water and 92 to 97 wt. % amrubicin hydrochloride; and a method of storing amrubicin hydrochloride. ... | 08/15/2006 |
| 7053191 | Method of preparing 4-R-substituted 4-demethoxydaunorubicin A method of synthesizing 4-R-substituted anthracyclines and their corresponding salts from 4-demethyldaunorubicin includes the steps of treating 4-demethyldaunorubicin with a sulfonylating agent to form 4-demethyl-4-sulfonyl-R3-daunorubicin. 4-Demethyl-4-... | 05/30/2006 |
| 7005421 | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside According to the invention there is provided a sterile, pyrogen-free, ready-to-use solution of an anthracycline glycoside, especially doxorubicin, which consists essentially of a physiologically acceptable salt of an anthracycline glycoside dissolved in a physiologi... | 02/28/2006 |
| 7001991 | Targeted delivery of bioaffecting compounds for the treatment of cancer A homogeneous conjugate for targeting and treating diseased cells wherein the conjugate comprises an anti-cancer drug and a targeting protein, wherein said anti-cancer drug is selected from the group consisting of heat sensitizers, photosensitizers and apoptosis ind... | 02/21/2006 |
| 6927211 | Method for reducing toxicity of combined chemotherapies Compositions and methods are provided for use in the treatment of cancer. ... | 08/09/2005 |
| 6921841 | Process for the synthesis of optically active anthracyclines It is described a process for the synthesis of optically active anthracyclines by the fact that the key intermediate (R)2-acetyl-2-hydroxy-1,2,3,4-tetrahydronaphtalene 5,8-dialkoxy-3,4-dihydronaphtalene by acylation asymmetric dihydroxylation, transformation into ch... | 07/26/2005 |
| 6914046 | NF-κB activation inhibitors, and their pharmaceutical uses Compounds inhibiting the activation of the nuclear factor κB (NF-κB) are used for the preparation of medications adapted for the treatment of malignant hemopathies and solid tumors, and for the prevention of the appearance or the treatment, of phenomena of resista... | 07/05/2005 |
| 6906040 | Method for reducing toxicity of combined chemotherapies Compositions and methods are provided for use in the treatment of cancer. ... | 06/14/2005 |
| 6844318 | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use This invention is directed to antineoplastic agents conjugated to enzyme-cleavable peptides comprising the amino acid recognition sequence of a membrane-bound and/or cell-secreted peptidase, and to the use of such conjugated compounds as chemotherapeutic agents in t... | 01/18/2005 |
| 6825166 | Molecular conjugates for use in treatment of cancer A molecular conjugate is provided having the formula: wherein n is the conjugation number, P is a moiety of a carrier molecule such as a protein, R1 is a moiety of a biologically active molecule or its analo... | 11/30/2004 |
| 6720306 | Tetrapartate prodrugs A compound of Formula I, providing tetrapartate prodrugs is provided wherein: L1 is a bifunctional linking moiety; D is a moiety that is a leaving group, or a residue of a compound to be delivere... | 04/13/2004 |
| 6716821 | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same Cytotoxic agents bearing a polyethylene glycol (PEG) linking group having a terminal active ester, cytotoxic conjugates comprising one or more cytotoxic agents linked to a cell-binding agent via PEG linking groups, and methods for producing both are disclosed. A the... | 04/06/2004 |
| 6709679 | Antineoplastic conjugates of transferin, albumin and polyethylene glycol Conjugates of transferrin, albumin and polyethylence glycol consisting of native or thiolated transferrin or albumin or of polyethylene glycol (MW between approximately 5,000 and 20,0000) with at least one HS—, HO— or H2N group and cytostatic compound... | 03/23/2004 |
| 6680300 | Methods and compositions for the manufacture of highly potent anthracycline-based antitumor agents The present invention discloses new and novel substituted anthracyclines having a three ring system or other DNA binding moieties. These congeners show high activity in vitro against several tumor cell lines. The invention also describes anthracycline-bas... | 01/20/2004 |
| 6677309 | Anti-cancer drug aldehyde conjugate drugs with enhanced cytotoxicity compounds, compositions and methods Monomeric and dimeric anti-cancer drug aldehyde conjugate compounds and pharmaceutically acceptable salts thereof. Specifically, monomeric and dimeric aldehyde conjugates of 1-2, dihetero-substituted anti-cancer drugs, including monomeric and dimeric alde... | 01/13/2004 |
| 6673907 | Methods and compositions for the manufacture of C-3' and C-4' anthracycline antibiotics The present invention discloses new and novel substituted anthracyclines with modified alkyl-aromatic ring substitutions on the C-3' of the sugar moiety or modified or unmodified alkyl-aromatic ring substitutions at the C-4' of the sugar moiety. It also d... | 01/06/2004 |
| 6670348 | Methods and compositions for destruction of selected proteins Compounds having an ansamycin anitibiotic, or other moiety which binds to hsp90, coupled to a targeting moiety which binds specifically to a protein, receptor or marker can provide effective targeted delivery of the ansamycin antibiotic leading to the deg... | 12/30/2003 |
| 6653455 | Crystallization of doxorubicin hydrochloride Disclosed are a crystallizing method of doxorubicin hydrochloride from a doxorubicin hydrochloride-containing solution, particularly a method for carrying out the crystallization under a condition of 40° C. or higher, and a doxorubicin hydrochloride crys... | 11/25/2003 |
| 6653289 | L-arabino-disaccharides of anthracyclines, processes for their preparation, and pharmaceutical compositions containing them The present invention refers to compounds of general formula (I), the pharmaceutically acceptable salts thereof, the processes for their preparation, and the pharmaceutical compositions containing them.... | 11/25/2003 |
| 6630579 | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use A cytotoxic agent comprising one or more modified doxorubicins/daunorubicin linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more modified doxorubicins/daunorubici... | 10/07/2003 |
| 6624142 | Trimethyl lock based tetrapartate prodrugs The invention is directed primarily to compounds of Formula I: ##STR1## wherein: R1 is a polymeric residue; L1 is a bifunctional linking group; Y1 and Y2 are independently O, S or NR7 ; R2-... | 09/23/2003 |
| 6596697 | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside According to the invention there is provided a sterile, pyrogen-free, ready-to-use solution of an anthracycline glycoside, especially doxorubicin, which consists essentially of a physiologically acceptable salt of an anthracycline glycoside dissolved in a... | 07/22/2003 |
| 6500936 | Pluraflavins and derivatives thereof, process for their preparation and use thereof The invention relates to a compound of formula (I) ##STR1## wherein R1 is a sugar; R2 is --CH2 --O--(R7)m, R7 representing a sugar, or is --COOH; R3 is an epoxide-comprising group, or is C | 12/31/2002 |
| 6437105 | Methods and compositions for the manufacture of highly potent anthracycline-based antitumor agents The present invention discloses new and novel substituted anthracyclines having a three ring system or other DNA binding moieties. These congeners show high activity in vitro against several tumor cell lines. The invention also describes anthracycline-bas... | 08/20/2002 |
| 6433150 | Anthracycline analogues bearing latent alkylating substituents Compound having the structure ##STR1## where anthracycline, N, Ra, X, Rb, n and m are as defined in the specification. The compound of the invention is activatable in vivo by esterases and spontaneous dehydration to form an aldehyde.... | 08/13/2002 |
